Ascentage Pharma Group International announced that its novel BTK-targeted protein degrader, APG-3288, has received IND clearance from the China CDE and is set to enter clinical study for relapsed/refractory hematologic malignancies. BTK mutations can lead to resistance to existing BTK inhibitors, creating a need for new treatment options. APG-3288 acts through degradation rather than inhibition, overcoming resistance and offering a promising therapeutic strategy. Ascentage Pharma’s strong presence in hematologic malignancies, with approved products in China, positions APG-3288 well for potential combinations in the pipeline. The Company aims to advance global clinical development for APG-3288 to address unmet clinical needs in patients with hematologic malignancies. Ascentage Pharma has established global partnerships with leading biotechnology and pharmaceutical companies, as well as research institutions. The company has a strong R&D portfolio and collaborations with organizations like Takeda, AstraZeneca, and Mayo Clinic. Forward-looking statements in their press release highlight future expectations and potential risks, urging caution in relying on these predictions. Ascentage Pharma emphasizes current beliefs and does not guarantee future accuracy. For more information, visit their website. Investor and media relations contacts are available for inquiries.

Read more at 1. Apple unveils new iPhone 12 with faster processor and 5G capabilities. – CNBC

2. Pfizer announces promising results in COVID-19 vaccine trial, with over 90% effectiveness. – Wall Street Journal

3. Amazon reports record-breaking sales on Prime Day, exceeding $3.5 billion. – Reuters

4. Tesla stock surges after company reports fifth consecutive profitable quarter. – CBS MarketWatch

5. Facebook faces antitrust lawsuit from FTC and 48 state attorneys general. – Barchart: Ascentage Pharma Announces IND Clearance by the China CDE